Pharmaceuticals News and Research

RSS

Spectrum Pharmaceuticals to be traded on NASDAQ Global Select Market

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced today that effective January 3, 2011, it will begin trading on the NASDAQ Global Select Market. The NASDAQ Global Select Market is the highest NASDAQ listing tier based on financial and liquidity criteria. Prior to the effectiveness of this change in the New Year, shares of Spectrum Pharmaceuticals will continue to be traded on the NASDAQ Global Market.

20 Dec 2010

King submits ACUROX NDA to FDA

King Pharmaceuticals®, Inc. and Acura Pharmaceuticals, Inc. today announced that King has submitted a New Drug Application (NDA) for ACUROX® (oxycodone HCl) Tablets to the U.S. Food and Drug Administration (FDA), including a request for priority review classification. ACUROX® is an immediate release tablet containing oxycodone HCl intended for the relief of moderate to severe pain.

20 Dec 2010

Positive top-line results from VEGF Trap-Eye Phase 3 studies in macular edema due to CRVO

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with macular edema due to central retinal vein occlusion (CRVO).

20 Dec 2010

Exciting progress made in MS research during 2010

Exciting advances were made in 2010 in virtually every field of MS research. Progress toward finding new therapies for MS is illustrated by the availability of the first oral disease-modifying therapy for MS. Progress was also made toward finding ways to restore function and improving quality of life and specific MS symptoms through exercise, meditation, rehabilitation and medications, including the first therapy specifically approved to treat a symptom of MS (Ampyra).

20 Dec 2010

Angiotech reaches agreement with Consenting Noteholders to extend deadlines under Recapitalization Support

Angiotech Pharmaceuticals, Inc. today announced that it has reached an agreement (the "Second Extension Agreement") with the holders (the "Consenting Noteholders") of a majority of the outstanding 7.75% Senior Subordinated Notes (the "Subordinated Notes") to extend certain deadlines outlined in the previously announced Recapitalization Support Agreement dated October 29, 2010 and amended on November 29, 2010 (as amended, the "Support Agreement").

20 Dec 2010

PwC: Top Health Industry Issues of 2011

Health organizations will undergo a strategy makeover in 2011 as they react to new rules and payment models, continuing cost pressures and new customer demands, according to the Top Health Industry Issues of 2011, published today by PwC's Health Research Institute. But in a recent nationwide survey of 1,000 U.S. adults, PwC found that consumers don't fully understand or buy-in to all the changes.

20 Dec 2010

SEEK announces new joint venture entity with Pernix Therapeutics for antitussive drug development

SEEK, a leading UK privately-owned drug-discovery group, is pleased to announce the establishment of a new joint venture entity with Pernix Therapeutics Holdings, an integrated specialty pharmaceutical company focused primarily on the United States pediatric market.

20 Dec 2010

FVCG invests $175,000 in Celvive for stem cell research in spinal cord injury

Spinal cord injury (SCI) is a devastating neurological condition with limited therapeutic options. In the United States alone, there are more than 250,000 people living with SCI; approximately three million worldwide are affected.

20 Dec 2010

BioNeutral Group, KHA to introduce Ogiene and Ygiene products

BioNeutral Group, Inc., a specialty life science technology-based company, today announced it is entering into discussions with the Kentucky Hospital Association (KHA) through its subsidiary Kentucky Hospital Services Corporation LLC (KHSC) to introduce BioNeutral's Ogiene™ and Ygiene™ products into its member hospital association.

20 Dec 2010

InterMune's MAA for Esbriet receives positive CHMP opinion

InterMune, Inc. today announced additions to its senior leadership team to prepare for the commercialization of Esbriet™ (pirfenidone) in Europe. InterMune's Marketing Authorization Application (MAA) for Esbriet received a positive CHMP opinion that is now awaiting ratification by the European Commission.

20 Dec 2010

Inspire's denufosol tetrasodium TIGER-1 Phase 3 trial for CF published in AJRCCM

Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.

20 Dec 2010

Cegedim Relationship Management establishes first office in Ukraine

Cegedim Relationship Management, the world's leading provider of Life Sciences-specific CRM solutions, today announced it has established its first office in Ukraine, as the company strengthen its relationship with and support of that country and the surrounding Russia and Commonwealth of Independent States.

20 Dec 2010

EpiTherapeutics, Abbott to develop new anti-cancer drugs

EpiTherapeutics and Abbott today announced a collaboration agreement to develop new anti-cancer drugs by making small-molecule inhibitors against selected epigenetic oncology targets.

20 Dec 2010

Avila, sanofi-aventis enter global alliance to discover targeted covalent drugs for treatment of cancers

Avila Therapeutics, Inc. announced today that it has signed a worldwide strategic alliance with sanofi-aventis to discover targeted covalent drugs for the treatment of cancers. Under the alliance agreement sanofi-aventis obtains a worldwide exclusive license to develop and commercialize the compounds resulting from the discovery collaboration.

20 Dec 2010

RXi's dermal anti-scarring candidate selected to advance into development

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today announced the selection of its first RNAi therapeutic product candidate to advance into development.

20 Dec 2010

Nation's anti-fraud efforts paying off, Holder says

At a summit held yesterday in Boston, Attorney General Eric Holder said the nation's crackdown on health care fraud and abuse is paying off, and Health and Human Services Secretary Kathleen Sebelius talked about new approaches that are contributing to such successes. Meanwhile, a new analysis names big pharma as the nation's "biggest defrauder" under the False Claims Act.

17 Dec 2010

MOCON board declares quarterly cash dividend of $0.095 per share

MOCON, Inc. announced today that on December 16, 2010, its Board of Directors declared a quarterly cash dividend of nine and one-half cents ($0.095) per share, payable on February 18, 2011, to shareholders of record on February 4, 2011.

17 Dec 2010

Mylan confirms lawsuit by Shionogi Pharma and CIMA LABS relating to generic Orapred ODT ANDA

Mylan Inc. today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Shionogi Pharma Inc. and CIMA LABS INC. in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg and 30 mg.

17 Dec 2010

Taiho receives CHMP positive opinion on Teysuno in combination with cisplatin for advanced gastric cancer

Taiho Pharmaceutical Co., Ltd., and its parent company, Otsuka Holdings Co., Ltd., announced today that the Committee for Medicinal Products for Human Use (CHMP), a division of the European Medicines Agency (EMA), has issued an opinion recommending approval of Teysuno™ (S-1), a novel oral anti-cancer agent, intended for the treatment of advanced gastric cancer in adults when given in combination with cisplatin.

17 Dec 2010

Patheon fourth quarter revenues increase 0.9% to $177.7 million

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today its results for the fourth quarter and full year ended October 31, 2010. Revenues for the fourth quarter were $177.7 million or 0.9 percent higher than the same period last year. Excluding currency fluctuations, current year fourth quarter revenues would have increased by approximately 5.0 percent versus the same period last year.

17 Dec 2010